Research Progress on Flavonoids in Traditional Chinese Medicine to Counteract Cardiotoxicity Associated with Anti-Tumor Drugs

作者全名："Shi, Hongwei; Duan, Lian; Tong, Li; Pu, Peng; Wei, Lai; Wang, Linlin; Hu, Desheng; Tang, Heng"

作者地址："[Shi, Hongwei; Wei, Lai; Hu, Desheng] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Dept Radiat Oncol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China; [Shi, Hongwei] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430064, Hubei, Peoples R China; [Duan, Lian; Pu, Peng; Tang, Heng] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing 400016, Peoples R China; [Tong, Li] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Hubei, Peoples R China; [Wang, Linlin] Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan 250117, Shandong, Peoples R China; [Tang, Heng] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Dept Cardiol, Chongqing 400038, Peoples R China"

通信作者："Hu, DS (通讯作者)，Huazhong Univ Sci & Technol, Hubei Canc Hosp, Dept Radiat Oncol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.; Tang, H (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing 400016, Peoples R China.; Wang, LL (通讯作者)，Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan 250117, Shandong, Peoples R China.; Tang, H (通讯作者)，Third Mil Med Univ, Army Med Univ, Southwest Hosp, Dept Cardiol, Chongqing 400038, Peoples R China."

来源：REVIEWS IN CARDIOVASCULAR MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001194074300005

JCR分区：Q3

影响因子：1.9

年份：2024

卷号：25

期号：3

开始页：　

结束页：　

文献类型：Review

关键词：traditional Chinese medicine; Flavonoid; anti -tumor drug -related cardiotoxicity; myocardial protection

摘要："The development of anti-tumor drugs has notably enhanced the survival rates and quality of life for patients with malignant tumors. However, the side effects of these drugs, especially cardiotoxicity, significantly limit their clinical application. The cardiotoxicity associated with anti-tumor drugs has been a subject of extensive attention and research. Traditional to mitigate these side effects have included reducing drug dosages, shortening treatment duration, modifying administration methods, and opting for drugs with lower toxicity. However, either approach may potentially compromise the anti-tumor efficacy of the medications. Therefore, exploring other effective methods for anti-cardiotoxicity will be the focus of future research. The potential of traditional Chinese medicine (TCM) in managing cardiovascular diseases and cancer treatment has gained widespread recognition. TCM is valued for its minimal side effects, affordability, and accessibility, offering promising avenues in the prevention and treatment of cardiotoxicity caused by anti-tumor drugs. Among its constituents, flavonoids, which are present in many TCMs, are particularly notable. These monomeric compounds with distinct structural components have been shown to possess both cardiovascular protective properties and anti-tumor capabilities. In this discussion, we will delve into the classification of anti-tumor drugs and explore the underlying mechanisms of their associated cardiotoxicity. Additionally, we will examine flavonoids found in TCM and investigate their mechanisms of cardiovascular protection. This will include an analysis of how these natural compounds can mitigate the cardiac side effects of anti-tumor therapies while potentially enhancing overall patient health and treatment outcomes."

基金机构："National Natural Science Foundation of China [82172865]; Chongqing Science and health joint project [2020FYYX101]; Biomedical Center Project of Hubei Cancer Hospital [2022SWZX27]; Innovation project of Wuhan Science and Technology Bureau [2023020201020519]; Natural Science Foundation of Hubei Province, China [2023AFB1046, 2019CFB407]; Chinese Medicine Program of Hubei Provincial Health Commission [ZY2021Q003]; Start-up fund of Shandong Cancer Hospital [2020-B14]; Wu Jieping Medical Foundation [320.6750.2021-02-51, 320.6750.2021-17-13]"

基金资助正文："The present study was supported by the National Natural Science Foundation of China (grant no. 82172865) , Chongqing Science and health joint project (grant no. 2020FYYX101) , Biomedical Center Project of Hubei Cancer Hospital (grant no. 2022SWZX27) , Innovation project of Wuhan Science and Technology Bureau (grant no. 2023020201020519) and the Natural Science Foundation of Hubei Province, China (grant no. 2023AFB1046, 2019CFB407) , Chinese Medicine Program of Hubei Provincial Health Commission (Grant number ZY2021Q003) , Start-up fund of Shandong Cancer Hospital (Grant number 2020-B14) , Clinical Research Special Fund of Wu Jieping Medical Foundation (Grant number 320.6750.2021-02-51 and 320.6750.2021-17-13) ."